Tas Faruk, Duranyildiz Derya, Argon Andac, Oğuz Hilal, Camlica Hakan, Yasasever Vildan, Topuz Erkan
Institute of Oncology, Istanbul University, Turkey.
Med Oncol. 2005;22(4):353-8. doi: 10.1385/MO:22:4:353.
In this study, we aimed to investigate the diagnostic and prognostic roles and the effects of chemotherapy of serum proinflammatory cytokines consisting of IL-6, TNF-alpha, CRP, and leptin levels in patients with advanced-stage non-small cell lung cancer. Twenty-eight patients newly diagnosed of non-surgical advanced non-small cell lung cancer and 15 healthy controls were included. All patients with good performance status were treated with combination therapy consisting of cisplatin plus vinorelbine chemotherapy. Blood samples were obtained in fasting conditions before chemotherapy first and after two cycles of chemotherapy. IL-6 and TNF-alpha immunoassays employ the quantitative sandwich enzyme immunoassay technique. Leptin (Sandwich) ELISA is a solid-phase enzyme-linked immunosorbent assay based on the sandwich principle. CRP is a photometric immunoturbidimetric test. Most of the patients were elderly, male predominance, good performance status, and no or less than 10% weight loss. Higher serum TNF-alpha (p < 0.001) and CRP (p < 0.001), and lower leptin (p = 0.021) levels in patients than in controls. Serum IL-6 cytokine (p = 0.693) levels were not significantly different. No statistically significant relationships between investigated serum parameters and various characteristics of patient and disease. Likewise, serum levels of leptin, IL-6, TNF-alpha, and CRP were all similar in lung cancer patients independently from severity of weight loss (p > 0.05). A direct relationship was found between serum IL-6 and TNF-alpha levels (r = 0.530, p = 0.004). We found that both serum leptin (p = 0.046) and IL-6 (p = 0.002) levels were decreased owing to the chemotherapy effect independently from chemotherapy response. However, serum TNF-alpha and CRP levels were not changed by the chemotherapy effect. The stage of the disease, serum LDH levels, performance status, and responsiveness to chemotherapy yielded prognostic value. Only serum IL-6 levels out of the parameters showed a trend (p = 0.06) related to a worse prognosis.
在本研究中,我们旨在探讨血清促炎细胞因子(包括白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)和瘦素水平)在晚期非小细胞肺癌患者中的诊断和预后作用以及化疗效果。纳入了28例新诊断的非手术晚期非小细胞肺癌患者和15名健康对照者。所有身体状况良好的患者均接受了顺铂加长春瑞滨联合化疗。在化疗前首次空腹时以及化疗两个周期后采集血样。IL-6和TNF-α免疫测定采用定量夹心酶免疫测定技术。瘦素(夹心)酶联免疫吸附测定(ELISA)是一种基于夹心原理的固相酶联免疫吸附测定。CRP是一种比浊免疫测定法。大多数患者为老年人,以男性为主,身体状况良好,且体重减轻不超过10%或未减轻。患者血清中TNF-α水平(p<0.001)和CRP水平(p<0.001)高于对照组,而瘦素水平(p=0.021)低于对照组。血清IL-6细胞因子水平(p=0.693)无显著差异。所研究的血清参数与患者及疾病的各种特征之间无统计学显著关系。同样,肺癌患者血清瘦素、IL-6、TNF-α和CRP水平与体重减轻严重程度无关,均相似(p>0.05)。发现血清IL-6和TNF-α水平之间存在直接关系(r=0.530,p=0.004)。我们发现,由于化疗效果,血清瘦素水平(p=0.046)和IL-6水平(p=0.002)均下降,且与化疗反应无关。然而,化疗对血清TNF-α和CRP水平无影响。疾病分期、血清乳酸脱氢酶(LDH)水平、身体状况以及对化疗的反应具有预后价值。在所研究的参数中,只有血清IL-6水平显示出与预后较差相关的趋势(p=0.06)。